Klivira
Request demo

Streamlining Medicaid Enhertu Prior Authorization

Effectively managing Medicaid Enhertu prior authorization demands a nuanced understanding of state-specific policies and the diverse requirements of Medicaid Managed Care Organizations (MCOs).

For revenue cycle directors and prior authorization coordinators, securing timely approvals for specialty drugs like Enhertu under Medicaid can be a significant operational challenge. The complex interplay of state Fee-for-Service (FFS) rules and varied MCO requirements often leads to administrative burden and delays in patient access.

The Nuance of Medicaid Prior Authorization for Specialty Oncology Drugs

Enhertu (trastuzumab deruxtecan) is an antibody-drug conjugate prescribed for HER2-positive/low breast cancer, HER2-positive gastric cancer, and NSCLC with HER2 mutation. As a high-cost specialty medication, it is a high-volume prior authorization target across commercial, Medicare Advantage, and Medicaid plans. Medicaid's decentralized, state-administered structure adds significant layers of complexity for PA submissions, requiring precise navigation of state-specific medical necessity criteria.

Medicaid Delivery Models and PA Routing for Enhertu

Medicaid programs operate through either Fee-for-Service (FFS) or Managed Care Organizations (MCOs). FFS submissions route to the state Medicaid agency's fiscal agent, while MCO submissions go to the specific MCO's provider portal. Most states utilize a hybrid model, requiring providers to accurately discern the correct pathway for each patient's Enhertu prior authorization request, adding to the administrative overhead.

Key Challenges in Medicaid Enhertu Prior Authorization

  • State-specific medical necessity criteria and policy libraries for specialty drugs.
  • Varying MCO formularies, step therapy requirements, and quantity limits.
  • Multiple submission channels, including state portals, MCO provider portals, and X12 278 routing.
  • Dynamic policy updates from state agencies and individual MCOs.
  • Coordination for dual-eligible (Medicare + Medicaid) members, including D-SNP considerations.

Leveraging Klivira for Medicaid Enhertu Prior Authorization Automation

Klivira automates the identification of the correct Medicaid delivery model and responsible MCO, applying relevant state Medicaid agency rules as the baseline for criteria. Our platform integrates with your EMR to streamline the submission process for Enhertu, reducing manual effort, improving data accuracy, and accelerating approval timelines across diverse Medicaid plans. This includes supporting X12 278 routing where available.

Compliance and Interoperability Considerations for Medicaid PA

Medicaid MCOs are impacted payers under CMS-0057-F, which mandates specific PA decision timeframes (72-hour standard, 24-hour expedited) and FHIR-based Prior Authorization API requirements, including Da Vinci PAS, on a phased timeline. While traditional FFS Medicaid is less directly impacted by the API requirements, it participates in broader interoperability provisions. Klivira's robust integration capabilities support compliance with these evolving standards, offering a clear path to discuss with your compliance team.

Frequently asked questions

How do state-specific rules impact Enhertu PA for Medicaid members?

Each state Medicaid agency publishes its own medical necessity criteria for specialty drugs like Enhertu, which MCOs cannot make more restrictive. Klivira helps navigate these varied state policy libraries to ensure accurate and compliant submissions, aligning with the specific requirements of the state where the patient resides.

Can Klivira handle both FFS and MCO Medicaid Enhertu prior authorizations?

Yes, Klivira is designed to identify the responsible Medicaid delivery model (FFS or MCO) and route the Enhertu prior authorization request to the appropriate state agency portal, MCO provider portal, or via X12 278 where supported. This ensures that each submission follows the correct operational pathway.

What are the typical turnaround times for Medicaid Enhertu PAs?

For Medicaid MCOs, CMS-0057-F mandates a 72-hour standard decision timeframe and a 24-hour expedited timeframe for prior authorization requests. FFS Medicaid timelines can vary by state, but Klivira helps optimize the submission process to meet these deadlines and accelerate patient access to critical oncology treatments.

Does Klivira integrate with EMRs for Medicaid Enhertu PA submissions?

Klivira offers deep EMR integration, leveraging SMART on FHIR capabilities, to pull necessary patient data directly for Enhertu prior authorization requests. This minimizes manual data entry, reduces the risk of errors, and ensures that all required clinical documentation is accurately submitted to the appropriate Medicaid payer.

How does Klivira address the variation in MCO policies for Enhertu?

Klivira's platform is built to account for the significant variation in MCO policies, formularies, and step therapy requirements for specialty drugs like Enhertu. By integrating with payer portals and leveraging advanced rules engines, Klivira ensures that each submission aligns with the specific MCO's criteria, helping to reduce denials.

Related coverage

Other enhertu prior authorization by payer

Other enhertu prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo